7 Best Peptides for Inflammaging

What to Know Before Choosing a Peptide for Inflammaging

Inflammaging is not a single condition with a single fix. It is a slow accumulation of overlapping biological processes: senescent cells releasing a cocktail of pro-inflammatory signals, mitochondria producing excess reactive oxygen species, a thymus gland that has shrunk and stopped generating enough naive T-cells, a gut lining porous enough to let bacterial endotoxins into circulation. Different peptides address different parts of that picture, which is why the field of compounds people use for this goal is broader and more varied than a single-mechanism problem would require.

Every compound in this guide earned its place by one standard: people use it or are actively discussing using it for inflammaging. That includes compounds with Phase II clinical trial data, compounds approved in other countries but not the United States, research-only compounds, and compounds whose evidence is largely experiential. Evidence strength is stated honestly inside each entry rather than used as a filter for whether a compound appears. A compound with only preclinical data or community-reported use still belongs here, with that reality stated plainly, because leaving it out would give the reader an incomplete map of what people actually reach for.

The entries are numbered, and those numbers reflect how prominently each compound appears in research and documented real-world use for inflammaging specifically. They are not a ranking of one compound being better than another for any individual. The compounds near the top have more published evidence and broader clinical discussion behind them. The compounds further down may have thinner published data but represent real and active use within the longevity and biohacking space. Personalized guidance, which compound fits your situation and how to approach it, is what MyPeptidePal is built to provide.

1. SS-31: For Mitochondria-Driven Systemic Inflammation

SS-31, also known as Elamipretide and by its earlier designations MTP-131 and Bendavia, is a synthetic tetrapeptide engineered specifically to reach the inner mitochondrial membrane, the part of the cell's energy-generating machinery that becomes progressively damaged with age. It belongs to the Szeto-Schiller class of mitochondria-targeting peptides, named for the researchers who developed it, and it is the most clinically advanced compound on this list by a meaningful margin.

Its primary target is cardiolipin, a specialized phospholipid found almost exclusively on the inner mitochondrial membrane. Cardiolipin plays a structural role in organizing the electron transport chain, the series of protein complexes that generate cellular energy. Think of cardiolipin as the scaffolding that holds the power plant's core machinery in alignment. With age and metabolic stress, cardiolipin becomes oxidized and damaged. When that happens, the electron transport chain loses efficiency, mitochondria produce excess reactive oxygen species, and those oxygen species act as a primary upstream trigger for the NLRP3 inflammasome, one of the central mechanisms driving chronic inflammation in aging tissue. SS-31 binds cardiolipin, stabilizes it against oxidation, and by doing so reduces the oxidative stress that feeds inflammaging at its source rather than further downstream.

The evidence base for SS-31 is more developed than for most compounds in the peptide space. It has completed Phase I and Phase II clinical trials, including the SPAR trial investigating skeletal muscle mitochondrial function in older adults, and multiple Phase II trials in heart failure with preserved ejection fraction, a condition with a strong inflammaging component. Those trials have generally shown a favorable safety profile alongside improvements in mitochondrial function and exercise capacity. It has attracted formal investigational new drug status and significant pharmaceutical development interest. What it does not yet have is full FDA approval or a completed large-scale Phase III trial, so it remains an investigational compound. In the biohacking and longevity community, it is discussed with considerable interest precisely because of that clinical development history, and it is used in research and off-label contexts. The specific mechanism, targeting mitochondrial dysfunction as a root cause of chronic inflammation rather than suppressing inflammatory signaling further downstream, is what distinguishes SS-31 within this field.

2. GHK-Cu: For Skin and Tissue Inflammaging

GHK-Cu is a naturally occurring tripeptide, glycine-histidine-lysine, complexed with copper. It is found in human plasma, saliva, and urine, and its circulating levels follow a trajectory that mirrors aging closely: relatively high in early adulthood and declining by roughly 60 percent by the sixth decade of life. That decline in an endogenous compound is part of why researchers and longevity-focused practitioners take it seriously.

The breadth of GHK-Cu's biological activity is unusual. It influences the expression of thousands of genes simultaneously, with reported effects on inflammatory cytokines including interleukin-6 and TNF-alpha, two of the central mediators of inflammaging. Preclinical studies have shown reductions in those markers of up to 60 percent in some models. The mechanism involves inhibition of NF-kB, the master transcription factor that drives chronic inflammatory gene expression, alongside simultaneous stimulation of collagen and elastin synthesis. That combination of anti-inflammatory and tissue-building effects in one compound is relatively uncommon among the peptides used in this space.

The human evidence for GHK-Cu is concentrated in topical applications for skin. More than 50 human studies have examined topical GHK-Cu for skin aging, wound healing, and tissue repair, making it the compound with the largest body of human trial data for skin-related inflammaging. The picture for systemic use via injection is different: injectable GHK-Cu has been removed from the approved compounding ingredient list in the United States due to regulatory concerns, so that route is not currently accessible through compliant domestic channels. Topical forms, ranging from serums to creams, remain widely available and represent the route with established human evidence behind it.

For anyone specifically addressing the skin manifestations of inflammaging, thinning, reduced resilience, slower wound healing, and the low-grade tissue inflammation that drives visible aging, GHK-Cu has the strongest human evidence base of any compound on this list. For systemic inflammaging addressed through injection, the evidence remains preclinical.

3. Thymosin Alpha-1: For Immune-Driven Chronic Inflammation

Thymosin Alpha-1 is a 28-amino acid peptide produced naturally by the thymus gland. Sold under the brand name Zadaxin, it is approved as a therapeutic in more than 35 countries for hepatitis B, hepatitis C, and immune support in cancer patients, though the United States is not among them. That international regulatory record, built on more than 30 clinical trials involving over 11,000 subjects, gives it one of the better-characterized safety profiles of any compound commonly discussed in the research peptide community.

The connection to inflammaging runs through immunosenescence, the age-related deterioration of immune function. As the thymus involutes with age, T-cell production falls, naive T-cells are depleted, and the immune system shifts toward a chronic pro-inflammatory state rather than a responsive and adaptive one. Thymosin Alpha-1 modulates toll-like receptors, specifically TLR2, TLR4, and TLR9, which are pattern recognition proteins on immune cells that calibrate the boundary between appropriate immune response and chronic inflammation. By recalibrating that balance, it functions as an immunomodulator rather than a broad anti-inflammatory: it does not suppress immune activity indiscriminately but works to restore appropriate immune signaling. That distinction matters for long-term use.

Clinical data shows reductions in interleukin-6 of roughly 38 to 44 percent in studied populations, alongside reductions in IL-1 beta and TNF-alpha. A 2024 safety review found no significant treatment-related adverse events across the trial record, and a 2025 meta-analysis showed reduced secondary infections in severe inflammatory conditions. In the United States, it is accessible through specialty compounding pharmacies with a physician prescription and via some telemedicine platforms. One significant contraindication to note: people on active immunosuppression for organ transplants should not use it, as it works against the immunosuppression those patients require and risks graft rejection.

For inflammaging driven primarily by immune dysregulation and the collapse of thymic function with age, Thymosin Alpha-1 is the most clinically grounded immunomodulating option on this list.

4. Epitalon: For Neuroendocrine and Pineal Regulation

Epitalon is a synthetic tetrapeptide, four amino acids in sequence (Ala-Glu-Asp-Gly), developed as an analog of epithalamin, a natural polypeptide secreted by the pineal gland. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, where it has been studied for decades as part of a broader investigation into peptide bioregulators for aging.

Several mechanisms connect it to inflammaging. Epitalon activates STAT1 phosphorylation independently of the usual ligand-receptor interaction, promoting immunological anergy, a dampening of excessive immune activation that can contribute to chronic low-grade inflammation. It also regulates pineal gland function and melatonin synthesis. Melatonin has established anti-inflammatory properties, and the pineal-neuroendocrine axis becomes dysregulated with age in ways that amplify inflammatory signaling. Additionally, the compound has been studied for its ability to activate telomerase, the enzyme responsible for maintaining telomere length. Shortened telomeres are closely linked to increased senescent cell burden, and senescent cells are among the primary producers of the SASP, the pro-inflammatory cytokine mix that drives much of what we call inflammaging.

The honest picture of the evidence is that most of Epitalon's data comes from Russian and Eastern European research institutes. Preclinical rodent studies have shown lifespan extension and reduced cancer incidence, and some observational human data from gerontological practice in Russia reports reduced all-cause mortality in elderly cohorts and antioxidant activity reducing oxidative-stress-driven inflammation. Large-scale randomized controlled trials published in mainstream Western peer-reviewed journals are sparse. This is a compound where the published human evidence is limited but the mechanistic rationale is substantive, and it has genuine and active use within longevity-focused communities. Injectable forms are the most researched route; nasal spray and oral forms also exist, though oral bioavailability is uncertain. It is available as a research chemical in Western markets and is not FDA-approved.

5. Thymalin: For Thymic Restoration and Immunosenescence

Thymalin is a peptide bioregulator complex derived from calf thymus tissue. It is part of the cytamine class of compounds developed by the Khavinson research group in Russia, containing multiple short peptides including thymogen, a glutamate-tryptophan dipeptide. It is related to but distinct from Thymosin Alpha-1 and Thymosin Beta-4.

The thymus gland undergoes progressive involution with age, shrinking and reducing its output of T-lymphocytes across adulthood. By middle age, thymic output is dramatically lower than in youth. This is not incidental to inflammaging; it is one of its structural drivers. As naive T-cell production falls, the immune system loses the capacity for targeted, specific responses to new threats, and shifts toward a generalized, chronic pro-inflammatory state instead. Senescent cell accumulation goes unchecked by effective immune surveillance, and the SASP output builds.

Thymalin's reported mechanism is upstream restoration of thymic function rather than direct suppression of downstream inflammatory cytokines. By partially restoring T-lymphocyte populations and improving the cytokine balance that a functional immune system produces, it addresses inflammaging at the level of immune competence. The Khavinson group has published long-term observational data, including 40-year follow-up on cohorts treated with thymus peptides, showing reduced mortality in elderly subjects. This work represents a meaningful body of research from within its originating context.

The evidence situation parallels Epitalon's: a body of research from Russian gerontological institutes, substantive mechanistic rationale, and limited Western randomized controlled trial data. It is used in clinical practice in Russia and parts of Eastern Europe and is available as a research chemical in Western markets. Injectable intramuscular administration is the primary studied route; oral capsule forms exist, with acknowledged uncertainty about bioavailability. For people specifically addressing the immunosenescence and thymic decline component of inflammaging, Thymalin and Epitalon are frequently discussed together in community and longevity literature, with Thymalin targeting thymic restoration and Epitalon targeting pineal and neuroendocrine regulation.

6. BPC-157: For Gut, Joint, and Musculoskeletal Inflammaging

BPC-157 is a 15-amino acid synthetic peptide derived from a protein found in human gastric juice. It is among the most widely used research peptides across multiple applications, and for inflammaging specifically its relevance is concentrated in gut mucosal integrity, musculoskeletal tissue, and localized joint inflammation, the tissue-level components of chronic low-grade systemic inflammation.

Its anti-inflammatory mechanism involves inhibition of NF-kB activation and reduction of TNF-alpha and interleukin-6 production, operating through several signaling pathways including Akt-eNOS, ERK1/2, and JAK-STAT. One frequently noted characteristic is that it reduces inflammation without blocking the prostaglandin pathways that tissues need for healing, which distinguishes its profile from standard non-steroidal anti-inflammatory drugs. It also promotes angiogenesis, the growth of new blood vessels into damaged or inflamed tissue, supporting the repair side of the inflammation-healing process.

The human clinical trial data is limited as of 2026. A small number of human pilot studies exist, and the preclinical data in gut, skin, and tissue repair models is robust. Community use is extensive, with user-reported benefits including resolution of longstanding gastrointestinal symptoms, reduction in joint pain and tendon inflammation, and faster musculoskeletal recovery. An important caution from community reporting: individuals with mast cell activation syndrome or ME/CFS have reported significant adverse reactions, including worsening cognitive and physical symptoms, so it is not universally well-tolerated. BPC-157 is not FDA-approved. Both injectable and oral forms are used, with the oral route showing particular relevance for gastrointestinal applications, and its compounding status has been subject to ongoing regulatory change.

7. MOTS-c: For Metabolic Inflammaging and Mitochondrial Signaling

MOTS-c is a 16-amino acid peptide with an origin unlike any other compound on this list: it is encoded within the mitochondrial genome itself, specifically within the 12S ribosomal RNA gene. It belongs to a newly characterized class called mitochondria-derived peptides, endogenous signals that mitochondria produce to regulate metabolism and stress responses throughout the body. Circulating MOTS-c levels naturally increase with exercise and decline with aging and metabolic disease, a pattern that fits its proposed role in the biology of inflammaging closely.

Its primary mechanism is activation of AMPK, which stands for AMP-activated protein kinase, a master metabolic regulator that acts as a cellular energy sensor. When AMPK is activated, it functions something like a switch that tells cells to stop storing and start managing energy more efficiently, and part of that efficiency involves dampening the inflammatory signaling that accompanies metabolic dysfunction. AMPK activation inhibits both NF-kB signaling and mTOR, two of the central pathways through which chronic inflammation is driven and maintained in aging tissue. MOTS-c also promotes mitophagy, the cellular process by which dysfunctional mitochondria are cleared before they accumulate and contribute further to oxidative stress and inflammatory signaling. This positions it as addressing metabolic inflammaging specifically, the form of chronic low-grade inflammation driven by insulin resistance, dyslipidemia, and the mitochondrial dysfunction underlying those conditions.

The evidence for MOTS-c is preclinical as of 2026. Cell culture and rodent studies have demonstrated AMPK activation, reduced metabolic inflammation, and improvements in insulin sensitivity. Preclinical lifespan extension data in mouse models has drawn research interest. No completed large-scale human clinical trials have been published for this compound as of 2026. What exists for human use is a growing community of longevity-focused users and practitioners working from the preclinical data and the biological rationale, making this primarily a community-reported use case. It is available as a research chemical, requires refrigeration, and has no standardized human protocol established. For someone specifically addressing the metabolic dimension of inflammaging, the mechanistic case is compelling, and the absence of human trial data is something to weigh honestly.

How These Peptides Compare

Frequently Asked Questions

What exactly is inflammaging and why does it matter for choosing a peptide?

Inflammaging is the chronic, low-grade, persistent inflammation that accumulates with age, distinct from the short-term inflammation that resolves after an injury or infection. It is considered a primary driver of most age-related diseases including cardiovascular disease, neurodegeneration, type 2 diabetes, and sarcopenia. Because inflammaging has multiple biological causes including mitochondrial dysfunction, thymic involution, senescent cell burden, and gut barrier breakdown, the most relevant peptide depends on which driver is most prominent in a given person's health picture.

Are any of these peptides FDA-approved for inflammaging?

No peptide on this list is FDA-approved specifically for inflammaging. SS-31 is the most advanced, having completed Phase I and Phase II clinical trials as an investigational drug. Thymosin Alpha-1 is approved as a therapeutic in more than 35 countries under the name Zadaxin, but not in the United States. GHK-Cu is approved as a cosmetic ingredient in topical form in the US, though its injectable form has been removed from compliant compounding. The remaining compounds are available as research chemicals or through off-label compounding channels with physician oversight.

Can these peptides be combined, or are they typically used on their own?

Community protocols frequently pair peptides targeting different aspects of inflammaging, for instance combining a mitochondria-focused compound with an immune-focused one. However, combination use adds complexity and individual variability that make it genuinely difficult to assess without a structured plan. No published clinical data on combination protocols for inflammaging exists as of 2026. The practical guidance on what to combine and in what context belongs in a personalized protocol built around individual circumstances.

How long before these compounds show any effect on inflammatory markers?

This varies considerably by compound and by the specific driver of inflammaging being addressed. Thymosin Alpha-1 has shown measurable changes in cytokine levels over weeks in clinical trial settings. Topical GHK-Cu studies report visible skin changes after roughly a month of consistent use. For Epitalon and Thymalin, the research framing is typically multi-week courses repeated periodically, with effects framed in terms of longer-term health outcomes rather than acute symptom change. Community-reported timelines for BPC-157 on gut and musculoskeletal applications range from days to several weeks. No compound on this list has a defined onset timeline for inflammaging as a primary measured endpoint in human trials.

What should someone do before starting any of these compounds?

Consulting a qualified healthcare professional is the practical first step, particularly because several of these compounds interact with immune function in ways that matter for specific populations. Thymosin Alpha-1 is contraindicated for people on active immunosuppression for organ transplants. BPC-157 has been reported to worsen symptoms in people with mast cell activation syndrome. Measuring baseline inflammatory biomarkers such as high-sensitivity CRP before starting gives you something concrete to track against. Because the regulatory status of several of these compounds continues to evolve, working with someone current on the landscape matters.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and real-world use of peptides for inflammaging in one place.